US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pacer WealthShield ETF

33.19

+0.80152.47%

Post-market: 33.08-0.1071-0.32%16:10 EST

Volume:600.00

Turnover:19.78K

Market Cap:31.53M

PE:- -

High:33.19

Open:32.86

Low:32.86

Close:32.39

52wk High:33.71

52wk Low:28.76

Shares:950.00K

Float Shares:950.00K

Volume Ratio:0.04

T/O Rate:0.06%

Dividend:0.52

Dividend Rate:1.55%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst

Benzinga_recent_news

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Bright Minds Biosciences Strengthens Advisory Board with PWS Experts

Press Release: Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR

Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study

Press Release: Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Tonix Pharmaceuticals to initiate PWS Phase 2 trial of TNX-2900 in 2026

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Acadia Pharmaceuticals PWS miss ‘disappointing but expected,’ says Leerink

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Benzinga_recent_news

Acadia Pharmaceuticals down 13% after COMPASS PWS trial misses endpoints

Wells sees Soleno’s shares trading up at least 20% on Acadia’s failure in PWS

Acadia Pharmaceuticals announces COMPASS PWS trial misses endpoints

Relmada Issues Mid-Year CEO Letter to Shareholders

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

Benzinga_recent_news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PWS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":33.1871,"timestamp":1770411600000,"preClose":32.3856,"halted":0,"volume":600,"hourTrading":{"tag":"盘后","latestPrice":33.08,"preClose":33.1871,"latestTime":"16:10 EST","volume":8,"amount":265.4968,"timestamp":1770412204539,"change":-0.1071,"changeRate":-0.003227,"amplitude":0},"delay":0,"changeRate":0.0247486537226423,"floatShares":950000,"shares":950000,"eps":0,"marketStatus":"Market Closed","change":0.8015,"latestTime":"02-06 16:00:00 EST","open":32.86,"high":33.1871,"low":32.86,"amount":19776.3518,"amplitude":0.0101,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":32.3856,"sharesOutstanding":950000,"nav":32.4,"aum":30780000,"dividendRate":0.015521,"bidAskSpread":0.001455,"postHourTrading":{"tag":"盘后","latestPrice":33.08,"preClose":33.1871,"latestTime":"16:10 EST","volume":8,"amount":265.4968,"timestamp":1770412204539,"change":-0.1071,"changeRate":-0.003227,"amplitude":0},"volumeRatio":0.04130581451025473},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":950000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.04130581451025473,"shares":950000,"dividePrice":0.5151,"high":33.1871,"amplitude":0.0101,"preClose":32.3856,"low":32.86,"week52Low":28.76,"pbRate":"--","week52High":33.71,"institutionHeld":0,"latestPrice":33.1871,"eps":0,"divideRate":0.015521,"volume":600,"delay":0,"ttmEps":0,"open":32.86,"prevYearClose":32.3237,"prevWeekClose":33.05,"prevMonthClose":33.05,"prevQuarterClose":32.3237,"fiveDayClose":33.05,"twentyDayClose":33.1169,"sixtyDayClose":33.1952},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"PWS","amount":0.25921895,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-05","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-05"},{"date":"2025-09-04","symbol":"PWS","amount":0.0796608,"announcedDate":"2025-09-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-04","defaultRemindTime":1756992600000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-10","payableDate":"2025-09-04","currency":"USD","dateTimestamp":1756958400000,"payDate":"2025-09-10"},{"date":"2025-06-05","symbol":"PWS","amount":0.116206,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-05","defaultRemindTime":1749130200000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-11","payableDate":"2025-06-05","currency":"USD","dateTimestamp":1749096000000,"payDate":"2025-06-11"},{"date":"2025-03-06","symbol":"PWS","amount":0.059681,"announcedDate":"2025-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-06","defaultRemindTime":1741271400000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-03-06","currency":"USD","dateTimestamp":1741237200000,"payDate":"2025-03-12"},{"date":"2024-12-27","symbol":"PWS","amount":0.206094,"announcedDate":"2024-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-27","defaultRemindTime":1735309800000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-02","payableDate":"2024-12-27","currency":"USD","dateTimestamp":1735275600000,"payDate":"2025-01-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602037667","title":"Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602037667","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602037667?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:00","pubTimestamp":1767963600,"startTime":"0","endTime":"0","summary":"-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 --  -- FY 2025 preli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216057/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2025-Net-Product-Revenues-and-Upcoming-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","PWS","VUS","EC"],"gpt_icon":0},{"id":"2601089231","title":"Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601089231","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601089231?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:16","pubTimestamp":1767701760,"startTime":"0","endTime":"0","summary":"BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability  Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213483/0/en/Bright-Minds-Biosciences-Announces-Positive-Topline-Results-from-Phase-2-Clinical-Trial-of-BMB-101-in-Patients-with-Absence-Seizures-and-Developmental-and-Encephalopathic-Epilepsie.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS"],"gpt_icon":0},{"id":"2591686624","title":"Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2591686624","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591686624?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:04","pubTimestamp":1765566240,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics gains an Outperform rating as its Phase 3 PWS trial progresses and analysts point to large market potential for ARD-101 and ARD-201.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PWS","AARD"],"gpt_icon":0},{"id":"2590515385","title":"Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515385","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590515385?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456200,"startTime":"0","endTime":"0","summary":"-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy --  -- Promising r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203809/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Data-from-Exploratory-Phase-2-Trial-that-showed-Setmelanotide-Demonstrated-Positive-Efficacy-Signal-in-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","VUS","PWS","EC"],"gpt_icon":0},{"id":"2590408558","title":"Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590408558","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590408558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:01","pubTimestamp":1765400460,"startTime":"0","endTime":"0","summary":"BOSTON, Dec.  10, 2025  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203492/0/en/Rhythm-Pharmaceuticals-to-Announce-Preliminary-Data-from-Exploratory-Phase-2-Trial-Evaluating-Setmelanotide-in-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","PWS","EC","VUS"],"gpt_icon":0},{"id":"2584675164","title":"Bright Minds Biosciences Strengthens Advisory Board with PWS Experts","url":"https://stock-news.laohu8.com/highlight/detail?id=2584675164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584675164?lang=en_us&edition=fundamental","pubTime":"2025-11-18 02:39","pubTimestamp":1763404750,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences ( ($TSE:DRUG) ) just unveiled an update. Bright Minds Biosciences has expanded its Scientific Advisory Board by adding fou...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bright-minds-biosciences-strengthens-advisory-board-with-pws-experts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bright-minds-biosciences-strengthens-advisory-board-with-pws-experts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PWS"],"gpt_icon":0},{"id":"2584405726","title":"Press Release: Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584405726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584405726?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:50","pubTimestamp":1763380200,"startTime":"0","endTime":"0","summary":"-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which was announced on November 6, 2025 --. NEW YORK and VANCOUVER, British Columbia, Nov. 17, 2025  -- Bright Minds Biosciences Inc.    today announced the addition of four global experts in Prader-Willi Syndrome  to its Scientific Advisory Board :. On November 6, 2025, the Company held a KOL event to announce the initiation of its PWS program and the nomination of BMB-105 as a new clinical candidate. A replay of the presentation is available in the Investor section of the Company's website under News & Events.Dr. Jennifer Miller is a Professor in the division","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","DRUG","LU1093756168.USD","LU2211817866.USD","LU2413666426.HKD","PWS","LU0347712357.USD","BK4585","BK4588","IE00BYQQ9H92.USD","MTD","LU1721428933.USD","FPWR","LU1093756325.SGD","BK4139","IE00BFXG0V08.USD","BK4567","BK4548","BK4533","LU2413666699.HKD"],"gpt_icon":0},{"id":"2581671769","title":"Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR","url":"https://stock-news.laohu8.com/highlight/detail?id=2581671769","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581671769?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290060,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Nov.  04, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180820/0/en/Soleno-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Update-on-U-S-Launch-of-VYKAT-TM-XR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4555","BK4099","BK4139","MAA","SLNO","TM","BK4588","BK4604","BK4585","BK4215","PWS"],"gpt_icon":0},{"id":"2578067674","title":"Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2578067674","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578067674?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:19","pubTimestamp":1761603554,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (($AARD)) announced an update on their ongoing clinical study. Study Overview: Aardvark Therapeutics, Inc. is conductin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-advances-pws-treatment-with-ard-101-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-advances-pws-treatment-with-ard-101-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARD","AARD","PWS"],"gpt_icon":0},{"id":"2575405141","title":"Press Release: Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2575405141","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575405141?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:00","pubTimestamp":1760356800,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Oct. 13, 2025  -- Soleno Therapeutics, Inc.  , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno's Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven seats.\"I am very pleased to welcome Mark to the Soleno Board as we continue to execute a strong commercial launch of VYKAT XR,\" said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. \"With his broad and diverse financial leadership experience, including as CFO of commercial-stage companies developing therapeutics for rare and serious diseases, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4099","BK4604","BK4588","SLNO","03160","PWS","BK4585","BK4139","TM"],"gpt_icon":0},{"id":"2573928291","title":"Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928291","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928291?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:00","pubTimestamp":1759924800,"startTime":"0","endTime":"0","summary":"Protocol Expansion to Ages 10+ Aligned with FDA Guidance, Broadening Patient PopulationSAN DIEGO, Oct.  08, 2025  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/08/3163296/0/en/Aardvark-Therapeutics-Announces-FDA-Alignment-on-Protocol-Amendment-Expanding-Phase-3-HERO-Trial-Population-for-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HERO","LU0128526141.USD","LU0708994859.HKD","CCK","LU0029864427.USD","LU0128525929.USD","LU0310799852.SGD","LU1267930573.SGD","LU1803068623.USD","BK4126","LU0310800379.SGD","LU1267930490.SGD","LU0211327993.USD","LU1892829315.USD","PWS","LU0029874061.USD","AARD","LU0211328371.USD"],"gpt_icon":0},{"id":"2571438770","title":"Tonix Pharmaceuticals to initiate PWS Phase 2 trial of TNX-2900 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2571438770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571438770?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:21","pubTimestamp":1759144888,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals (TNXP) announced plans to progress its TNX-2900 program for the treatment of Prader-Willi syndrome into a Phase 2 clinical tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tonix-pharmaceuticals-to-initiate-pws-phase-2-trial-of-tnx-2900-in-2026-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tonix-pharmaceuticals-to-initiate-pws-phase-2-trial-of-tnx-2900-in-2026-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PWS","BK4139","TNXP","BK4583"],"gpt_icon":0},{"id":"2571387675","title":"Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387675","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387675?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:00","pubTimestamp":1759143600,"startTime":"0","endTime":"0","summary":"Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 grant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3157566/28908/en/Tonix-Pharmaceuticals-Plans-to-Initiate-Prader-Willi-Syndrome-Phase-2-Trial-of-TNX-2900-Intranasal-Potentiated-Oxytocin-in-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4161","LU0029874061.USD","HI","BK4139","LU2360032135.SGD","LU2125154778.USD","TNXP","LU2125154935.USD","BK4135","BK4583","PWS","LU0128526141.USD"],"gpt_icon":0},{"id":"2569905083","title":"Acadia Pharmaceuticals PWS miss ‘disappointing but expected,’ says Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2569905083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569905083?lang=en_us&edition=fundamental","pubTime":"2025-09-24 23:15","pubTimestamp":1758726910,"startTime":"0","endTime":"0","summary":"Leerink says while disappointed that Acadia Pharmaceuticals (ACAD)’ ACP-101 missed its primary endpoint, the firm had low expectations going into t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acadia-pharmaceuticals-pws-miss-disappointing-but-expected-says-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acadia-pharmaceuticals-pws-miss-disappointing-but-expected-says-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4231","PWS","LU2065169927.USD","BK4139","BK4080","LU2065171402.SGD","LU2065170008.USD","ACAD","AKR","LU2065171311.SGD"],"gpt_icon":0},{"id":"2569700518","title":"Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short","url":"https://stock-news.laohu8.com/highlight/detail?id=2569700518","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569700518?lang=en_us&edition=fundamental","pubTime":"2025-09-24 22:05","pubTimestamp":1758722700,"startTime":"0","endTime":"0","summary":"Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/24/Prader-Willi-Syndrome.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/24/Prader-Willi-Syndrome.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/09/47841758/acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/09/47841758/acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PWS","AKR","BK4231","BK4080"],"gpt_icon":0},{"id":"2569735706","title":"Acadia Pharmaceuticals down 13% after COMPASS PWS trial misses endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2569735706","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569735706?lang=en_us&edition=fundamental","pubTime":"2025-09-24 19:55","pubTimestamp":1758714909,"startTime":"0","endTime":"0","summary":"Acadia shares are down 13% to $20.46 in pre-market trading after the company announced intranasal carbetocin did not demonstrate a statistically si...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acadia-pharmaceuticals-down-13-after-compass-pws-trial-misses-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acadia-pharmaceuticals-down-13-after-compass-pws-trial-misses-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4080","PWS","BK4231","AKR"],"gpt_icon":0},{"id":"2569841706","title":"Wells sees Soleno’s shares trading up at least 20% on Acadia’s failure in PWS","url":"https://stock-news.laohu8.com/highlight/detail?id=2569841706","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569841706?lang=en_us&edition=fundamental","pubTime":"2025-09-24 19:35","pubTimestamp":1758713718,"startTime":"0","endTime":"0","summary":"Wells Fargo believes Acadia Pharmaceuticals’ (ACAD) Phase 3 failure removes a near-term competitor to Soleno Therapeutics’ (SLNO) VYKAT XR. Wells t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wells-sees-solenos-shares-trading-up-at-least-20-on-acadias-failure-in-pws-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wells-sees-solenos-shares-trading-up-at-least-20-on-acadias-failure-in-pws-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2361044865.SGD","LU0251142724.SGD","LU0211328371.USD","IE0002270589.USD","LU1668664300.SGD","BK4080","LU0208291251.USD","BK4207","LU0708994859.HKD","PWS","LU0971096721.USD","LU2361044949.HKD","LU0314106906.USD","BK4559","LU0980610538.SGD","LU1267930490.SGD","LU0251131958.USD","SLNO","LU1074936037.SGD","IE00B19Z3581.USD","LU1035773651.USD","LU0175139822.USD","LU0477156953.USD","LU0267386448.USD","LU2065169927.USD","LU0320765489.SGD","LU1363072403.SGD","LU1506573853.SGD","BK4585","IE00B7SZLL34.SGD","ACAD","LU0787776722.HKD","LU1267930227.SGD","BK4504","LU0029864427.USD","LU0162691827.USD","LU0742534661.SGD","LU0149725797.USD","AKR","BK4588","LU0128525689.USD","LU0052756011.USD","BK4231","LU0070302665.USD","LU0048573561.USD","LU0130102774.USD","LU0683600562.USD","LU2361045086.USD","LU2065170008.USD","LU2461242641.AUD"],"gpt_icon":0},{"id":"2569055857","title":"Acadia Pharmaceuticals announces COMPASS PWS trial misses endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2569055857","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569055857?lang=en_us&edition=fundamental","pubTime":"2025-09-24 19:10","pubTimestamp":1758712221,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals (ACAD) announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbet...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acadia-pharmaceuticals-announces-compass-pws-trial-misses-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acadia-pharmaceuticals-announces-compass-pws-trial-misses-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065170008.USD","BK4080","LU2065171311.SGD","AKR","ACAD","BK4139","BK4231","LU2065169927.USD","PWS","LU2065171402.SGD"],"gpt_icon":0},{"id":"2566960802","title":"Relmada Issues Mid-Year CEO Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2566960802","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566960802?lang=en_us&edition=fundamental","pubTime":"2025-09-10 19:15","pubTimestamp":1757502900,"startTime":"0","endTime":"0","summary":"CORAL GABLES, Fla., Sept.  10, 2025  (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies fo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/10/3147651/0/en/Relmada-Issues-Mid-Year-CEO-Letter-to-Shareholders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR","PWS"],"gpt_icon":0},{"id":"2559943952","title":"Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe","url":"https://stock-news.laohu8.com/highlight/detail?id=2559943952","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559943952?lang=en_us&edition=fundamental","pubTime":"2025-08-16 01:30","pubTimestamp":1755279000,"startTime":"0","endTime":"0","summary":"Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face market withdrawal.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/15/Shanghai-china-dec-28th-2023-Soleno-Ther.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/15/Shanghai-china-dec-28th-2023-Soleno-Ther.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/08/47163394/short-seller-alleges-soleno-only-commercial-drug-overpriced-and-unsafe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/08/47163394/short-seller-alleges-soleno-only-commercial-drug-overpriced-and-unsafe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["MAA","BK4081","BK4215","EMA","PWS","BK4588","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}